The treatment of PIK3CA-related breast cancers has been a major focus in breast cancer research, and the combination of PI3K/AKT inhibitors with rapamycin has been explored as a potential treatment option [63,114,143,144,145,146]. The gene discussed is AKT1; the disease is breast carcinoma.